bluebird bio (BLUE) Q1 2025 earnings summary

Executive summary

• Entered into a Merger Agreement with Beacon Parent Holdings, L.P.; tender offer commenced for all outstanding shares, with closing expected in the first half of 2025.

• Focused on commercializing three FDA-approved gene therapies: ZYNTEGLO, SKYSONA, and LYFGENIA, with all product revenue in the U.S.

• Significant financial and operational risks if the Merger Transaction does not close, including risk of bankruptcy due to loan default.

Financial highlights

• Q1 2025 net product revenue was $38.7M, up from $18.6M in Q1 2024, driven by eight additional infusions.

• Net loss for Q1 2025 was $29.1M, a significant improvement from $69.8M in Q1 2024.

• Gross margin improved to $26.5M from a negative $7.3M year-over-year.

• Cash and cash equivalents as of March 31, 2025 were $78.7M; accumulated deficit reached $4.5B.

• Operating expenses decreased to $51.1M from $71.4M year-over-year, reflecting lower SG&A and R&D costs.

Outlook and guidance

• Existing cash and equivalents expected to fund operations into June 2025 and through anticipated Merger closing, assuming continued cost-saving and vendor payment deferrals.

• If the Merger does not close by June 20, 2025, immediate loan default and risk of bankruptcy are anticipated.

• No new clinical trials planned in Europe; U.S. commercialization remains the focus.